FTSJ1 Inhibitors

The chemical class referred to as FTSJ1 Inhibitors consists of a variety of compounds that can influence the activity of the FTSJ1 protein indirectly by modulating the availability of substrates or the methylation context within the cell. FTSJ1, being a methyltransferase, relies on the presence of S-adenosylmethionine (SAM) as a methyl donor for its enzymatic function. Compounds such as Ademetionine and Folic Acid are directly involved in the production and regeneration of SAM within the cell. Overabundance or deficiency in these compounds can lead to competition for substrate or a lack of methyl donor availability, respectively, which in turn can modulate FTSJ1 activity.

Other compounds, like Decitabine, Hydralazine, RG108, and 5-Azacytidine, are inhibitors of DNA methyltransferases and can affect the methylation landscape of the cell, leading to a secondary impact on FTSJ1 activity. These effects can arise because changes in DNA methylation can lead to alterations in gene expression, including that of genes encoding proteins that interact with or regulate FTSJ1. Moreover, compounds such as MTA, Sinefungin, and the SAH Hydrolase inhibitor 3-Deazaneplanocin A can increase the intracellular concentration of S-adenosylhomocysteine (SAH), an inhibitor of methyltransferases, which can lead to a reduction in FTSJ1 activity. Cycloleucine and Homocysteine act upstream to affect the concentrations of SAM and SAH, thereby impacting FTSJ1 activity indirectly.